CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.

Welcome to Pulmonary Pharmacology & Therapeutics, a leading journal dedicated to the dissemination of innovative research and insights in the fields of pulmonary medicine and pharmacology. Published by Academic Press Ltd - Elsevier Science Ltd, this journal has made significant contributions to the academic community since its inception in 1997, with an ongoing commitment to relevant advancements projected through to 2024. With reputable Q2 rankings across vital categories including Biochemistry (medical), Medicine (miscellaneous), Pharmacology (medical), and Pulmonary and Respiratory Medicine, Pulmonary Pharmacology & Therapeutics is ranked in the top tier of its field, reflecting its impact on the discipline as evidenced by its Scopus rankings. Researchers, healthcare professionals, and students alike can access a wealth of high-quality articles that address the complexity of pulmonary diseases and therapeutic strategies, supporting research and clinical practice alike. Join the vibrant community contributing to this essential field and explore the latest findings that can drive change in patient care and therapeutic effectiveness.

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is a pivotal open-access journal published by Elsevier Science Inc., dedicated to the advancing field of clinical and experimental pharmacology. Established in 1959, this esteemed journal is committed to providing a platform for the dissemination of innovative research findings that span the entire spectrum of therapeutic sciences. With an impact factor that reflects its focus on enhancing medical knowledge and practice, CURRENT THERAPEUTIC RESEARCH serves a diverse audience of researchers, healthcare professionals, and students, striving to bridge the gap between laboratory research and clinical application. The journal has achieved a Q3 ranking in both the pharmacology and medical pharmacology categories, signifying its contribution to the field. With its open-access model initiated in 2006, it underscores the importance of research accessibility, ensuring that valuable insights reach a global audience. As the journal continues to evolve, it remains an essential resource for those devoted to improving therapeutic interventions and advancing healthcare outcomes through rigorous scientific inquiry.

Therapeutic Advances in Drug Safety is a prestigious open-access journal published by SAGE Publications Ltd that has made significant strides in the field of pharmacology since its inception in 2010. With an impressive impact factor that places it in the Q1 category for Pharmacology (medical), this journal ranks 61st out of 272 in Scopus, showcasing its global influence and commitment to advancing drug safety research. Based in the United Kingdom, it aims to bridge the critical gap between pharmacological innovation and clinical application, offering a platform for the dissemination of groundbreaking research, case studies, and expert reviews. Since adopting an Open Access model in 2019, the journal has significantly increased its reach, ensuring that vital findings in drug safety are accessible to researchers, healthcare professionals, and educators worldwide. As the field of drug safety continues to evolve, Therapeutic Advances in Drug Safety remains an essential resource for those dedicated to enhancing safe therapeutic practices and patient outcomes.

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

Frontiers in Pharmacology, published by FRONTIERS MEDIA SA, stands as a leading open-access journal dedicated to advancing the field of pharmacology since its inception in 2010. With its ISSN 1663-9812, the journal is based in Switzerland and maintains a vital role in disseminating innovative research findings that span various disciplines within pharmacology, including pharmacokinetics, toxicology, and pharmacogenetics. In 2023, Frontiers in Pharmacology has achieved an impressive standing within the scientific community, being ranked in the Q1 category for both general and medical pharmacology, highlighting its critical contribution to the field with a Scopus ranking of #41 out of 272 in medical pharmacology and #76 out of 313 in pharmacology, toxicology, and pharmaceutics, placing it in the 75th and 85th percentiles, respectively. Researchers and practitioners benefit from its open-access model, which ensures widespread accessibility to groundbreaking research, fostering collaboration and innovation across the pharmaceutical sciences. With its commitment to excellence, Frontiers in Pharmacology serves as an essential resource for those looking to explore and contribute to the latest advancements in pharmacological research.